NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2
Updated: May 26, 2022
A.R.R.O.W.2
NCT03859427: Phase 3: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)
KRd
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.
Sponsor
Amgen
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT03859427
Official Title: A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)
First Posted : March 1, 2019
Click here to see details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Locations
United States, California
United States, Colorado
United States, Connecticut
United States, Florida
United States, Illinois
United States, New York
United States, Ohio
United States, Texas
Europe
France
Germany
Netherlands
Spain
Austria
Bulgaria
Czechia
Finland
Greece
Lithuania
Romania
Slovakia
Sweden
Turkey
Asia
Japan
Russian Federation